$408.18 0.7%
VRTX Stock Price vs. AI Score
Data gathered: December 25

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Vertex Pharmaceuticals (VRTX)

Analysis generated July 28, 2024. Powered by Chat GPT.

Vertex Pharmaceuticals is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company primarily focuses on creating treatments for cystic fibrosis (CF) and has a robust pipeline of potential therapies to target various life-threatening diseases. By integrating cutting-edge technology and unparalleled scientific expertise, Vertex Pharmaceuticals aims to substantially improve the quality of life for patients globally.

Read full AI stock Analysis

Stock Alerts - Vertex Pharmaceuticals (VRTX)

company logo Vertex Pharmaceuticals | December 19
Price is down by -12.7% in the last 24h.
company logo Vertex Pharmaceuticals | December 10
Over the past few months, there has been an upward trend in Web Traffic.
company logo Vertex Pharmaceuticals | December 9
Ro Khanna (member of U.S. congress) is buying shares
company logo Vertex Pharmaceuticals | November 15
Price is down by -5.3% in the last 24h.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.


Vertex Pharmaceuticals
Price $408.18
Target Price Sign up
Volume 1,470,000
Market Cap $104B
Year Range $392.81 - $516.74
Dividend Yield 0%
PE Ratio 32.11
Analyst Rating 62% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '242.77B764M2.01B1.05B04.380
Q2 '242.65B744M1.9B-3.59B-3.47B-12.830
Q1 '242.68B685M1.99B1.1B1.19B4.760
Q4 '232.49B782M1.7B969M1.02B4.200
Q3 '232.47B583M1.89B1.04B1.24B4.080

Insider Transactions View All

Biller Jonathan filed to sell 16,651 shares at $461.7.
October 3 '24
Bhatia Sangeeta N. filed to sell 4,435 shares at $500.
September 4 '24
LEIDEN JEFFREY M filed to sell 9,994 shares at $499.
September 4 '24
Bhatia Sangeeta N. filed to sell 4,435 shares at $466.3.
August 12 '24
Bozic Carmen filed to sell 23,259 shares at $476.8.
August 8 '24

Congress Trading View All

Politician Filing Date Type Size
Ro Khanna
Dec 6, 24 Buy $1K - $15K
Ro Khanna
Oct 8, 24 Buy $1K - $15K
Rohit Khanna
Democrat
Nov 8, 23 Buy $1K - $15K

What is the Market Cap of Vertex Pharmaceuticals?

The Market Cap of Vertex Pharmaceuticals is $104B.

What is Vertex Pharmaceuticals' PE Ratio?

As of today, Vertex Pharmaceuticals' PE (Price to Earnings) ratio is 32.11.

What is the current stock price of Vertex Pharmaceuticals?

Currently, the price of one share of Vertex Pharmaceuticals stock is $408.18.

How can I analyze the VRTX stock price chart for investment decisions?

The VRTX stock price chart above provides a comprehensive visual representation of Vertex Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Vertex Pharmaceuticals shares. Our platform offers an up-to-date VRTX stock price chart, along with technical data analysis and alternative data insights.

Does VRTX offer dividends to its shareholders?

As of our latest update, Vertex Pharmaceuticals (VRTX) does not offer dividends to its shareholders. Investors interested in Vertex Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Vertex Pharmaceuticals?

Some of the similar stocks of Vertex Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.